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Abstract
Background: The difficulty in elucidating the genetic basis of complex diseases roots in the many
factors that can affect the development of a disease. Some of these genetic effects may interact in
complex ways, proving undetectable by current single-locus methodology.
Results: We have developed an analysis tool called Hypothesis Free Clinical Cloning (HFCC) to
search for genome-wide epistasis in a case-control design. HFCC combines a relatively fast
computing algorithm for genome-wide epistasis detection, with the flexibility to test a variety of
different epistatic models in multi-locus combinations. HFCC has good power to detect multi-locus
interactions simulated under a variety of genetic models and noise conditions. Most importantly,
HFCC can accomplish exhaustive genome-wide epistasis search with large datasets as
demonstrated with a 400,000 SNP set typed on a cohort of Parkinson's disease patients and
controls.
Conclusion: With the current availability of genetic studies with large numbers of individuals and
genetic markers, HFCC can have a great impact in the identification of epistatic effects that escape
the standard single-locus association analyses.
Background
Most common diseases have an etiology so complex that
years of research have yielded scarce results towards the
elucidation of their causes. Technology and methodology
are improving quickly but results have been arriving
slowly. Nonetheless, optimism is in the air, because large
studies of many individuals and genetic markers seem to
finally be revealing some of the genetic factors behind
these common diseases [1].
The difficulty of elucidating the genetic basis of complex
diseases roots in the many factors that can affect the devel-
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opment of a disease. Many factors, both genetic and envi-
ronmental, each with possibly only a small effect, may be
necessary for the expression of a particular disease pheno-
type. For example, most associations reported in the
recent wave of genome-wide association studies of differ-
ent common diseases exhibited small (1.1–1.4) to moder-
ate (1.5–2) odds ratios [2].
These small effects may only be detectable by means of
genetic association analysis in very large samples, or in
smaller sub-samples in which, by sample selection, this
effect is enlarged: a sub-sample where the allele frequency
of a particular risk gene is increased; or a sub-sample
where a combination of other alleles or environmental
factors act to increase the observable effect of a particular
gene [3].
Many genes may contribute to the expression of complex
diseases. It is quite reasonable to expect that the effects of
some of these genes do not sum up in a simple fashion.
Epistasis generally refers to an interaction between the
effects of genes at different loci, although the term has
been used in different contexts by different disciplines [4].
Some of these genetic effects may interact among them,
such that the presence of two or more particular genes
may increase the risk to a disease more than expected from
their independent effects, the expectation being derived
from a pre-defined model, such as additive or multiplica-
tive. For example, the odds ratio for an epistatic effect of
two genes may be larger, even much larger, than the com-
bined effect (sum or product) of each of the two single
genes [5,6]. Moreover, there are biological models of
epistasis where genes only have epistatic effects [7], such
as a two-locus mutation masking a known phenotype.
Some of these genetic effects may prove undetectable by
current single-locus methodology [8]. There have been
some early attempts to search for epistatic effects [5,9-11],
but there is currently a need for methods to study this
important genetic phenomenon, perhaps key for complex
diseases.
A wealth of current research in molecular genetics has dis-
covered millions of genetic markers which provide a good
coverage of common genetic variation across the entire
human genome [12]. At the same time, advances in geno-
typing technology have greatly increased the quantity and
quality of genotypes. Current genotyping platforms can
generate millions of genotypes in short periods of time.
These events have made possible the genetic association
analysis of a trait across the entire genome.
Although the arrival of genome-wide association testing is
great news for the genetic dissection of complex traits, the
large number of statistical tests involved raises the issue of
statistical significance. For example, to maintain a Type I
error of 5 percent when testing 100,000 markers for
genetic association may require a test-statistic with a prob-
ability value of 5 × 10-7, if a Bonferroni correction is
applied. Nonetheless, many of these markers are corre-
lated so this correction would be too strict, but in any case
the required p-value would be very small.
This problem of multiple testing is even more extreme for
the test of epistasis. For example, for 100,000 markers,
there are a total of 5 × 10+9 two-locus combinations,
which would require a Bonferroni-corrected p-value of 1
× 10-11 for a genome-wide significance level of 0.05, which
again would be overly conservative due to the correlated
nature of many of these tests. To achieve these significance
levels it is necessary to study large samples and expect to
find large epistatic effects.
Replication of findings in independent samples is sought
for growing confidence in statistical results. The lack of
replication of association results may be due to different
causes, some technical (low power due to small samples,
bad quality of phenotypic or genotypic data, uncorrected
noise or covariates) and some biological (heterogeneity of
effects or population-specific risks). An approach to tackle
the multiple testing issue is to divide the available sample
into independent groups and to carry out the analysis in
these independent groups to look for consistent results
across the groups. Some true genetic effects will be missed
due to lack of power (due to the reduced sample in each
group) and to heterogeneity, but this approach may allow
the identification of moderate/large-sized epistatic effects
that are frequent and consistent.
In this scenario, we have developed an analysis tool to
search for genome-wide epistasis in a case-control design.
Hypothesis Free Clinical Cloning (HFCC) is an stan-
dalone software which allows for single-locus genetic
association testing, as well as epistasis testing for multi-
locus combinations of markers. Due to the intense com-
putational burden, it is programmed to take advantage of
computer clusters by dividing the tasks into processes
which can migrate to the available CPUs. We present here
the method, as well as a genome-wide two-locus epistatic
analysis performed on a real dataset of Parkinson's disease
that illustrates the method. With the current availability of
genetic studies with large numbers of individuals and
genetic markers, HFCC can have a great impact in the
identification of epistatic effects that escape the standard
single-locus association analyses.
Methods
Input Data
Sample
The standard input to HFCC is a case-control sample with
hundreds or thousands of individuals. Similarly to otherBMC Genomics 2008, 9:360 http://www.biomedcentral.com/1471-2164/9/360
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association methods, it is convenient that cases and con-
trols are matched for potentially important covariates like
age, sex, ethnicity, geographical location, environmental
factors, etc. Dichotomous phenotypes with a potential
effect on the trait may be used as covariates in the analysis.
If all cases have only one disease phenotype or trait, HFCC
carries out a single-phenotype analysis. In the single-phe-
notype scenario, HFCC can analyze the full sample simul-
taneously for extra statistical power. In addition, we have
developed a multi-group analysis strategy, explained in
more detail in a later section, that allows the replication of
consistent results, and it also aids the elimination of false
positives results, a very attractive quality for genome-wide
analysis of large number of genetic markers. For this sin-
gle-phenotype multi-group analysis option, cases can be
sub-divided into groups to allow for replication of con-
sistent results across these groups. Controls can also be
sub-divided into groups to eliminate spurious associa-
tions.
Nonetheless, one of the strengths of HFCC is that it can
analyze multiple phenotypes simultaneously. For this
multiple-trait analysis, several groups of cases with differ-
ent but related phenotypes are formed, each matched to
its own control group. Indeed, the multi-group analysis
strategy is especially convenient for the simultaneous
analysis of several related diseases, or different symptoms
of a syndrome, so that we can identify the genetic effects
common to the different groups.
Genotypes
HFCC can currently analyze di-allelic markers such as sin-
gle nucleotide polymorphisms (SNP), and it can also
accommodate other dichotomous markers such as the
presence or absence of a particular allele of a multi-allelic
marker or of a haplotype. HFCC can analyze anything
from small sets of candidate gene markers to genome-
wide arrays of hundreds of thousands of markers.
Markers can be filtered out before analysis if they have low
call rate, low minor allele frequency, or if they fail a
Hardy-Weinberg equilibrium test. Nonetheless, data anal-
ysis filters inherent in the software can eliminate, at least
partly, these problematic markers.
Currently, linkage disequilibrium (LD) among markers is
ignored during the analysis, although it is useful for the
validation and interpretation of results.
Datasets
To illustrate the method we used data from the SNP
Resource at the NINDS Human Genetics Resource Center
DNA and Cell Line Repository http://ccr.coriell.org/
ninds/. The original genotyping was performed in the lab-
oratory of Drs. Singleton and Hardy (NIA, LNG),
Bethesda, MD USA [13]. We have used data on 270
patients with Parkinson's disease and 271 normal control
individuals who were genotyped for 396,591 SNPs in all
22 autosomal chromosomes using the Illumina Infinium
I and Infinium II assays. Cases were all unrelated white
individuals with idiopathic Parkinson's disease and age of
onset between 55–84 years (except for 3 young-onset
individuals). The control sample was composed of neuro-
logically normal, unrelated, white individuals from the
USA.
To explore the power of HFCC we also analyzed a simu-
lated dataset that was originally generated to evaluate the
power of a different gene-gene interaction method [14].
These case-control data were simulated under different
genetic models, and different sources of noise (genotyp-
ing error, missing data, phenocopy and genetic heteroge-
neity). For each genetic model and noise condition, 100
datasets were generated. Each dataset contains 200 cases
and 200 controls, with genotypes for 10 SNPs under
HWE. An epistatic effect with no single-locus marginal
effect was simulated for a pair of SNPs, and the remaining
8 SNPs were simulated under the null hypothesis of no
genetic effect. For the genetic heterogeneity case, two epi-
static effects (each due to a different pair of SNPs) were
simulated. More detail of these simulated datasets can be
found in the original publication [14].
HFCC Modelling
Statistical tests
Single-Locus Association tests
HFCC can perform a single-locus genome-wide associa-
tion scan. A di-allelic marker with alleles A and B, has 3
possible genotypes: AA, AB and BB. For each genetic
marker, HFCC performs three statistical tests, comparing
each genotype against the other two. For example, the fre-
quency of the AA genotype is compared against the com-
bined frequency of the AB-BB genotypes, in cases and
controls. This could be considered a dominance model
test for the B allele. Similarly, recessive (BB versus AA-AB)
and heterozygote models (AB versus AA-BB) are also con-
sidered. The test for association between the established
genotypic classes and the case-control groups can be a
Wald test or a chi-squared test with one degree of freedom
(df).
Multi-Locus and Epistatic Association tests
HFCC can also perform a multi-locus genome-wide asso-
ciation scan. For a two-locus scan, HFCC first forms all
possible combinations of two markers from all available
markers. For each two-marker combination (marker 1
with alleles A and B, and marker 2 with alleles C and D),
there are 9 possible genotypic classes (AACC, AACD,
AADD, ABCC, ...., BBDD), and a total of 512 fully pene-BMC Genomics 2008, 9:360 http://www.biomedcentral.com/1471-2164/9/360
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trant disease models [7]. For our purpose, this number of
models can be reduced to 255, because some models are
redundant or represent a model with no genetic effect.
These 255 models include a variety of standard models
(single-locus, double-recessive, double-heterozygote, etc.)
as well as other rare models. The user can select to test all
available models or a subset of them.
As in the single-locus case, the statistical test involves
comparing the frequency of two sets of genotypic classes
in cases versus controls. The two sets of genotypic classes
are defined by the model being tested. For example, in the
case of the double-recessive model, the frequency of the
BBDD genotypic class is compared against the combined
frequency of all other genotypes (AACC through BBCD),
in cases and controls, from which a Wald-test Z statistic,
or a chi-squared statistic with one degree of freedom, can
be obtained.
Another analysis option is a more general multi-locus test
[6] which compares two chi-squared statistics with four
degrees of freedom (one obtained for cases and the other
one for controls). This test, although more general, may
not be able to detect some disease models.
For a three-locus scan, there are 27 possible genotypic
classes, and the software is currently implemented to test
the 27 simplest 3-locus genetic models, comparing the fre-
quency of a genotypic class (ie, AACCEE) against the com-
bined frequency of all other genotypes.
Post-Hoc tests
A variety of post-hoc statistical tests are included in the
post-hoc analysis software, named Alambique. For single-
locus analysis, it is possible to carry out Hardy-Weinberg
equilibrium, heterozygous, homozygous, allele positivity
(dominance), recessive, common odds ratio (Armitage's
trend) [15], and genotypic (2 degrees of freedom) tests.
For the two-locus analysis, all 255 fully-penetrant models
can be tested. Moreover, interaction indices can be esti-
mated to determine to which extent an observed two-
locus association deviates from an additive model [16].
Finally, departures from a multiplicative model can be
tested using a case-only chi-squared test [17].
These post-hoc analyses are useful to determine which
genetic model explains better an observed association,
and to measure the epistatic component of associated
multi-locus combinations.
Grouping
Replication (Case versus control) groups
The statistical tests for association of a trait with a marker
are based on the differential frequency between cases and
controls of a particular allelic or genotypic combination.
Comparing the full sample of cases versus the full sample
of controls is the most powerful approach to find statisti-
cally significant associations. Nonetheless, to evaluate
genomewide association or epistasis we need to test a very
large number of markers or marker combinations, which
in turn can produce a large number of spurious results.
Therefore, we need to improve the filtering of false-posi-
tive results, at the expense of increasing the false-negative
findings.
We have approached this multiple-testing issue by parti-
tioning the available sample into multiple replication
groups. Cases are selected randomly to be part of one and
only one case group, and similarly for control individuals
and control groups. Then, the statistical analysis is per-
formed on each of the paired case-control groups, and
results that are consistent across all replication groups are
selected. This sample-splitting technique may prove less
powerful to detect positive results in general, but provides
a powerful tool to eliminate false positives, thereby high-
lighting potentially true effects that are consistent across
samples. The number of groups into which the sample is
partitioned can be chosen by the user depending on the
study design, and the number of subjects and markers
available for analysis.
This multi-group strategy is one of the differentiating
aspects between HFCC and conventional association
methods, and it is particularly useful for the analysis of
multiple related phenotypes. Case groups are directly
defined by phenotypic criteria, and control groups are
matched to each case group. This type of analysis can
reveal genetic associations that are common to these phe-
notypes, revealing a common etiology for multiple symp-
toms of a disease, or for several related diseases [18].
Control filter (Control versus control) groups
HFCC has developed an efficient noise filter, by applying
the association tests to independent groups of controls.
Positive results that arise from a comparison of two
groups of controls must be spurious associations due to
marker or sample characteristics. These spurious associa-
tions can be filtered out of the results from the case-con-
trol analysis, providing an efficient sample-specific
background noise filter.
Algorithm and program execution
HFCC requires specific data and parameter files. The input
data file is a simple-text matrix of integers in which rows
represent genetic markers and columns represent individ-
uals. Each integer represents the genotype for one individ-
ual at one marker, coded as 0 for missing, 1 for one
homozygote, 2 for the heterozygote, and 3 for the other
homozygote. These integers are entered sequentially, withBMC Genomics 2008, 9:360 http://www.biomedcentral.com/1471-2164/9/360
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no blank spaces or lines, to save space. There is one data
matrix for each group of cases (F1.txt, F2.txt, etc.), controls
(C1.txt, C2.txt, etc) and noise-filter controls (CF1.txt,
CF2.txt, etc.), as can be seen in Figure 1. A parameter data
file defines the type of analysis (single- or multi-locus;
genetic model; test statistic), number of genetic markers,
number of groups, sample size per group, statistical cut-
off for significance, and other necessary parameters.
The following algorithm describes HFCC analysis flow
(Figure 1). Genetic markers are analyzed sequentially in
the order in which they are entered in the data matrices.
First, HFCC selects a marker variable (either a single-locus
marker or a multi-locus combination of markers, depend-
ing on the type of analysis). Then, for the selected analysis
model, it computes genotype frequencies and test statis-
tics in each replication group, sequentially. If the test sta-
tistic is smaller than a pre-defined cut-off in any of the
replication groups, the marker variable is dropped at that
stage and no more computations are performed on this
marker variable to save processing time. If the test statistic
is larger than the cut-off in all replication groups, then the
marker variable is written to the output file and also
entered in the control noise filter. This noise reduction
analysis computes frequencies and test statistics in each
control filter (control versus control) group sequentially.
If the test statistic is larger than a pre-defined cut-off in any
of the filter groups, the marker variable is flagged for
removal from the final output file. The marker can fail at
any of the sequential group analyses (replication or con-
HFCC data groups and algorithm Figure 1
HFCC data groups and algorithm. HFCC data groups are divided into cases (F), controls (C) and control filter (CF). The 
number of replication groups is experiment-specific and depends on the available dataset (sample size and number of genetic 
markers). The HFCC algorithm is defined by a particular analysis flow. For each marker variable (single-locus markers, two-
locus marker combinations, etc. depending on the type of study), a sequential number of tests is performed. Case-controls 
comparisons are performed on each replication group, and control-control comparisons are carried out in each control filter 
group. If any of these tests is not beyond a statistical threshold, the marker variable is dropped, and the next marker variable is 
analyzed. Marker variables over the statistical threshold in all case-control tests, and below the threshold in all control-control 
tests, are selected.
F1
C1
CF1
F2
C2
CF2
Replication groups (1, 2, …, n)
Case-Control
Comparisons
Control-Control
Comparisons
(Noise filter)
…
…
…
Select marker variable
F1 vs. C1 test
F2 vs. C2 test
Fn vs. Cn test
C1 vs. CF1 test
C2 vs. CF2 test
> cut-off
> cut-off
> cut-off
< cut-off
Dropped
HFCC Analysis Flow
< cut-off
Dropped
< cut-off
Dropped
Cn vs. CFn test
> cut-off
Dropped
> cut-off
Dropped
> cut-off
Dropped
< cut-off
< cut-off
< cut-off
Output File
HFCC Data Groups
Fn
Cn
CFn
…
…
…BMC Genomics 2008, 9:360 http://www.biomedcentral.com/1471-2164/9/360
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trol filter group comparisons), at which point that marker
is dropped to save processing time. This procedure is
repeated for all possible marker variables, writing to the
output file all associations considered statistically signifi-
cant. This output file contains the marker (or marker com-
bination) and the genetic model for which it yielded a
positive association (ie, for a two-locus combination:
marker 1, genotypic class 1, marker 2, genotypic class 2).
These selected marker variables can then be included in
two sequential post-hoc analyses which aid in the inter-
pretation of the results. The first post-hoc analysis yields
odds ratios and chi-squared values for all selected marker
variables. It also applies a direction filter, by selecting only
those results which display the same direction of effect in
all replication groups, and writes a new output file, which
contains only those marker variables with a significant
and consistent effect (same direction and same model) in
all replication groups.
The second post-hoc analysis (Alambique) identifies the
best type of genetic model for each association selected in
the first post-hoc analysis. For this reason, all replication
groups are combined into a single group, that is, all cases
in one case group and all controls in a control group.
Alambique has its own noise elimination algorithm,
denominated tracking filter. Many of the selected associa-
tions are due to what we call a tracking marker, a locus
with a very large marginal effect. Many of these tracking
markers are not in HWE and are filtered at this stage. In
any case, having a large marginal effect makes a locus
appear in many two-locus associations, because the large
effect tracks other loci. Because our focus is on finding epi-
static interactions, the many positive associations due to
these tracking effects can be filtered out and analyzed
independently. For the remaining marker variables, which
have passed this tracking filter, there is one analysis
option that groups the two-locus results into those with
marginal effects for only one locus (conditional effect), or
for both loci (simultaneous effect) or those without mar-
ginal effects (epistatic effect) [19]. Some of the condi-
tional and simultaneous results may still exhibit epistatic
effects if the two-locus effect size deviates from an additive
or multiplicative expectation, and these epistatic effects
can also be flagged. A second analysis option tests all 255
fully-penetrant models in selected marker variables, to
help choosing the model that best fit the data.
Due to the extremely time-consuming and computer-
intensive nature of these analyses, especially for genom-
ewide multi-locus analysis, it will often be necessary to
run HFCC under a small selection of genetic models, and
then use Alambique to identify the best genetic model for
the selected markers. The number and selection of genetic
models to analyze will depend on the phenotype, the
dataset, previous knowledge and computer resources
available.
Results
We have applied HFCC to both simulated and real data-
sets to illustrate the power and the functioning of the
method.
Simulated data analysis
To evaluate the power of the method, we analyzed a sim-
ulated dataset published previously [14]. Data were simu-
lated under three types of two-locus epistasis models:
Model 1 was a logical XOR model, a combination of
exactly one heterozygous and one homozygous loci (i.e.,
for two markers with alleles A, B and C, D respectively, risk
genotypes would be ABCC, ABDD, AACD and BBCD),
similar to M170 [7] but with variable penetrances; Model
2 involved the inheritance of exactly two, and only two,
risk alleles (i.e., A and C) from any of two different loci
(i.e., risk genotypes would be AADD, ABCD, and BBCC),
such as M84 [7]; Model 3 was a variable penetrance risk
model with a protective double-heterozygote (i.e., protec-
tive genotype would be ABCD), similar to M16 [7]. In
addition, to make the simulated data more similar to real
data, and therefore to evaluate the effect of noise in the
detection of these epistatic effects, different sources of
noise were modeled in the simulations. For each of the
three types of genetic models described above, the data
was simulated and analyzed under six types of noise:
without noise, with 5% genotyping error (GE), with 5%
missing data (MS), with 50% phenocopy (PC), with 50%
genetic heterogeneity (GH), and with all sources of noise
simultaneously. For more information on these simulated
datasets please refer to the original publication [14].
Power was defined as the proportion of times the correct
model was detected out of each set of 100 simulations.
For genetic heterogeneity the correct model was defined as
detection of either one of the two epistatic loci simulated.
To detect potential epistatic loci, we ran HFCC two-locus
analysis with nine simple genetic models, the M1, M2 and
M16 models [7]. There are a total of 45 possible two-locus
combinations that can be formed with the 10 simulated
genetic markers. Due to this relatively small number of
tests (relative to a genome-wide study), HFCC was per-
formed with only one group of cases and controls, and a
chi-square cut-off of 6.64 (approximately a p-value = 0.01
with 1 degree of freedom). Using only one case-control
group allows also for direct comparison of HFCC's power
to the power estimates published previously for this data-
set. Results from the SNPs simulated under the null
hypothesis reveal fewer Type I errors than expected, con-
firming that the method is not biased and perhaps con-BMC Genomics 2008, 9:360 http://www.biomedcentral.com/1471-2164/9/360
Page 7 of 14
(page number not for citation purposes)
servative. This reduced number of false positives may
reflect that some of the epistasis tests used were correlated,
as well as a general lack of power to detect some epistatic
effects, especially for rare genotypes.
HFCC had excellent power (>96%), with a Type I error of
0.01, to detect the simulated two-locus interactions under
most genetic models and noise conditions, including gen-
otyping error and missing data (See Table 1). Genetic het-
erogeneity reduced the power to 82% under model 3, and
the presence of phenocopies had also a significant impact
on power for models 1, and especially, 3. Finally, if all
four sources of noise were acting simultaneously the
power was reduced to 51% for model 1, 71% for model 2,
and 34% to model 3.
Parkinson's disease analysis
To demonstrate the HFCC software in real data we ana-
lyzed the open-access Parkinson's dataset described in the
Methods section. We included all 396,591 SNP markers.
Many of them had low minor allele frequencies or failed
Hardy-Weinberg equilibrium (HWE), but were included
in order to test the data filters inherent in HFCC, which
are meant to eliminate, at least partially, these problem-
atic markers.
The 270 cases and 271 controls were separated into
groups, to illustrate HFCC multi-group analysis strategy.
We created 3 replication groups of 90 cases each (groups
F in Figure 1) and 3 groups of controls of approximately
similar size (C in Figure 1; one group with 91 individuals
and two groups of 90 individuals). Because of the lack of
more control individuals, the noise filter control groups
(CF in Figure 1) were selected respectively from each of
the control groups, chosen so that the noise filter would
not pair two identical control groups (ie, CF1 = C3; CF2 =
C1; and CF3 = C2). Ideally, independent groups of C and
CF controls would be used, so we expected that the noise
filter in this experiment, in which the same groups of con-
trols were used as C and CF, would not be as effective.
To detect potential epistatic loci, we ran HFCC two-locus
analysis with nine simple genetic models, the M1, M2 and
M16 models [7]. These nine genetic models were tested in
all possible (78.6 × 10+9) two-locus marker combinations.
In order to be considered a preliminary positive result, the
chi-squared (1 df) cut-off value was set at 6.64, which
yields a probability value of 0.01 for each replication
group (p < 10-6  over all three replication groups).
Although this p-value may be considered low compared
to the number of statistical tests performed, this is only a
cut-off to select preliminary positive results, which are
then filtered and subjected to post-hoc analysis to select
the most promising results. We obtained a total of
418,535 preliminary two-locus associations at this p-
value cut-off (Table 2). To evaluate the impact of the dif-
ferent noise filters (control, direction and tracking) we
applied them selectively to these preliminary results.
Noise filters (control, direction, tracking)
Direction filter
When the control filter is not used, the direction filter has
a large impact on the number of results selected. Of the
418,535 preliminary associations, only 76.5 % (320,265)
had effects in the same direction in all replication groups.
These results can then be grouped into those with mar-
ginal effects in both loci (simultaneous), only one mar-
ginal effect (conditional), and no marginal effect
(epistatic). A marginal effect was defined as a single-locus
effect with a chi-squared (1 df) statistic larger than 3.84
(p-value < .05). This liberal cut-off serves our goal of
selecting as pure epistatic effects those marker combina-
tions with no or small marginal effects. Under these crite-
ria, 22.3% (71,332) of the results had simultaneous
marginal effects, 77.7% (248,898) had conditional
effects, and only 0.01% (35) had epistatic effects. At this
point, out of the hundreds of thousands of preliminary
results, only 35 two-locus associations without marginal
effects remained, very likely to be epistatic interactions.
The many thousand simultaneous and conditional results
may also involve epistatic effects on top of the marginal
effects, but the large number of them prevents a thorough
post-hoc analysis.
Direction and Tracking filters
In order to distil further the post-direction-filter results we
can apply the tracking filter. Many of these two-locus asso-
ciations are due to what we have denominated tracking
loci, that is, markers with large marginal effects, which
Table 1: Power Analysis.
Power (%)
Noise Model 1 Model 2 Model 3
None 100 100 99
GE 100 100 96
MS 100 100 97
PC 89 100 49
GH 100 100 82
G E + G H + P C + M S 5 17 13 4
Power of HFCC to detect a two-locus interaction at an alpha level of 
0.01 under 3 genetic epistasis models and different sources of noise: 
no noise (None), genotyping error (GE), missing data (MS), 
phenocopy (PC), genetic heterogeneity (GH), and all sources of noise 
simultenously (GE+GH+PC+MS). For the datasets with genetic 
heterogeneity, we reported the power to detect either of the two 
simulated two-locus effects. Model 1 is a heterozygote-homozygote 
risk (i.e., risk genotypes ABCC, ABDD, AACD and BBCD); Model 2 
represents a "2 and only 2"-allele risk (i.e., A and C) from any of two 
loci (i.e., risk genotypes AADD, ABCD, and BBCC); Model 3 
represents a protective double-heterozygote (i.e., protective 
genotype ABCD).BMC Genomics 2008, 9:360 http://www.biomedcentral.com/1471-2164/9/360
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therefore display significant two-locus effects with many
other markers. Most of these tracking markers exhibit
large association effects because they fail HWE, and they
are filtered out at this stage. In this Parkinson dataset we
detected 36 tracking markers, defined as those markers
showing up in 270 or more two-locus associations (top
0.1% of post-direction-filter results). Most of these track-
ing markers (83.3%) failed HWE (p < 0.001 in controls or
<0.0001 in cases), and others failed minor allele fre-
quency (MAF<0.1) or call rate (CR<90%) criteria. There-
fore, results involving these markers can be safely
excluded.
A few of these tracking markers represent the best single-
locus association results which, due to their large mar-
ginal effects, also appear in a large number of two-locus
association results. These large-single-locus-effect tracking
markers need their own specific post-hoc analysis.
Because of their large marginal effects, these markers are
likely identifiable by single-locus analysis, but it is still
noteworthy to discover if they have epistatic effects, and
with which genes. However, it is hard to identify a signif-
icant epistatic interaction in the background of such a
large marginal effect. Individual post-hoc analysis for each
of these markers may identify the most likely multi-locus
combination involving those marker.
Interestingly, by filtering out the marker combinations
involving the tracking markers, we can eliminate 91.8% of
the previous positive results. Most of these results were
conditional effects, involving the tracking locus (with a
large single-locus effect) and a tracked locus (with no
main effect, but tracked by the large effect in the other
locus). The post-tracking-filter results include a total of 35
marker variables with epistatic effects, 6,706 with condi-
tional effects, and 19,630 with simultaneous effects.
Control, Direction and Tracking filters
We can repeat this data filtering process, but this time
starting by applying the control noise filter. The control
filter was set to employ the same statistical cut-off (chi-
squared = 6.64) used in the case-control comparisons.
Association results above this cut-off value obtained in
analysis of two control groups can be deemed problem-
atic and excluded from further analysis. This control filter
was able to eliminate 18.75% of the preliminary results,
leaving a total of 340,043 associations (81.25%). Apply-
ing the direction filter to the post-control-filter results
eliminates only a further 5.84% of preliminary results,
yielding a total of 320,188 associations, almost exactly the
same quantity as when the direction filter was used alone.
Therefore, the control and direction filters seem to elimi-
nate most of the same results, which reassures their correct
functioning and also allow for different analysis strategies.
On one hand, when enough control subjects are not avail-
able and consequently the control filter can not be used,
these results suggest that the direction filter may work well
alone. On the other hand, the direction filter may not be
useful for some multiple-phenotype studies, expecting
effects on different directions in different replication
groups. Thus, in some scenarios, the control and tracking
filters may provide enough noise elimination by them-
selves.
When the tracking filter was applied to the results selected
by the control and direction filters, we obtained 35 two-
locus combinations with epistatic effects, 6,701 with con-
ditional effects, and 19,611 with simultaneous effects. By
applying three consecutive data filters (control, direction
and tracking), we excluded almost 94% of the preliminary
results. The remaining 6.3% of results are subsequently
analyzed for departures of additive or multiplicative two-
locus models, to estimate their potential for epistatic
effects.
Table 2: HFCC analysis: Preliminary results and effect of noise filters.
Applied Filters Unfiltered Results After Control Filter After Direction Filter After Tracking Filter Selected two-locus SNP pairs
Simultaneous Conditional Epistatic
Method I
N 418,535 - 320,265 - 71,332 248,898 35
% 100% - 76.5% - 17.0% 59.5% 0.01%
Method II
N 418,535 - 320,265 26,371 19,630 6,706 35
% 100.0% - 76.5% 6.3% 6.1% 2.1% 0.01%
Method III
N 418,535 340,043 320,188 26,347 19,611 6,701 35
% 100.0% 81.2% 76.5% 6.3% 6.1% 2.1% 0.01%
Method I: Only Direction Filter applied.
Method II: Direction and Tracking filters applied.
Method III: All filters applied (Control, Direction, and Tracking filters sequentially in that order).
N: Number of selected two-locus SNP pairs.
%: Percentage of selected two-locus SNP pairs over the preliminary set (unfiltered HFCC results).
A total of 36 SNPs were identified as tracking SNPs in the two methods using tracking filter.BMC Genomics 2008, 9:360 http://www.biomedcentral.com/1471-2164/9/360
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Epistatic interaction indices
HFCC analysis yielded 35 two-locus combinations with
epistatic effects and no noticeable single-locus marginal
effects, ten of which are displayed in Table 3. In addition,
there are 26,312 conditional or simultaneous two-locus
combinations, which may display interaction effects over
and above the marginal effects. There are a variety of tests
and indices to detect departures from additive or multipli-
cative models. For example, a case-only chi-squared test
can detect two-locus interactions which deviate from a
multiplicative model. For the present study, this case-only
statistic was used to choose, among the conditional and
simultaneous marker variables, those with the most sig-
nificant interactions (Table 3). In addition, marker quality
control criteria were checked to assure all markers in
selected combinations passed a minimum requirement
(HWE p-value > 0.001 in controls and >0.0001 in cases;
MAF>0.1; call rate>90%).
Validation analysis
In order to validate to some extent these results, and with-
out immediate access to a truly independent sample, we
created 10 validation samples by randomly re-creating the
case groups (F) from the full pool of cases (N = 270), and
similarly for the control groups (C). In the described anal-
ysis of the Parkinson dataset, three replication groups
were created randomly, to find consistent results across
these groups. To examine the possible effect of this ran-
dom group membership, the replication groups were re-
created randomly and reanalysed in what we called vali-
dation experiments. These validation experiments are not
permutation simulations to estimate the empirical signif-
icance level of parameter estimates, and are not a standard
bootstrapping technique because they use sampling with-
out replacement. The replication groups in each valida-
tion analysis were re-created under association (keeping
cases as cases and controls as controls), and not under the
null hypothesis of no association. These validation exper-
iments are used to examine the consistency of results
when the replication groups are re-created.
The control noise filter was not employed for these valida-
tions analyses to save computing time, since it was found
that for this dataset the direction and tracking filters alone
Table 3: Selected Parkinson's disease two-locus combinations.
SNP1 SNP2 Effect Genetic Model Odds Ratio 2-locus X2 Case-only X2
rs6542522 rs3923511 E TC*GA 0.28 24.97 13.07
rs10799573 rs1341622 E CC*CT 5.22 23.08 10.61
rs12520264 rs2992630 E AG*GA 0.22 23.86 23.12
rs324454 rs12672177 E GG*AG 0.21 24.31 11.55
rs6656554 rs3898966 E GT*TC 3.83 23.44 22.34
rs7650598 rs12353255 E AG*AG 3.99 23.94 9.40
rs2439525 rs1327918 E TT*CC 2.39 22.04 7.13
rs10201616 rs4495512 E CT*TT 5.04 24.08 8.63
rs11167062 rs1270919 E TC*GT 0.20 21.83 20.65
rs2419117 rs10512174 E GT*CC 5.55 23.33 9.33
rs1370699 rs1673130 C CC*CC 0.35 25.50 30.15
rs1590957 rs8043401 C TT*AG 0.32 24.17 28.18
rs1557615 rs2582597 C TC*AG 0.35 21.76 26.38
rs11781101 rs4775501 C CC*CC 0.22 23.99 25.69
rs1370699 rs7897163 C CC*CC 0.34 30.65 25.68
rs13197142 rs2206699 C GG*AA 2.33 21.85 25.16
rs732594 rs12373417 C AA*GG 3.62 22.31 25.16
rs10498269 rs1551355 C TC*CC 0.38 23.42 25.00
rs2555614 rs331617 C AA*TT 0.35 24.15 24.22
rs3894377 rs10774863 C AG*CT 0.31 25.47 23.84
rs4799327 rs2301661 S AG*CC 4.32 20.65 33.62
rs2336865 rs7973385 S GA*TC 3.22 30.71 27.77
rs6779648 rs270406 S GG*AG 0.26 26.57 22.49
rs12599027 rs767055 S TT*TT 0.23 26.23 24.34
rs3891371 rs4724620 S AG*CC 0.29 35.76 23.92
rs2297518 rs660454 S AG*TT 0.12 23.92 23.72
rs357968 rs1159145 S AA*AA 0.26 30.29 23.47
rs1476097 rs5766305 S TT*TT 0.37 23.93 23.19
rs2955005 rs2169793 S GT*AG 3.29 25.74 22.76
rs2560790 rs9390939 S AA*CA 0.32 23.35 22.62
A selection of two-locus marker combinations consistently and significantly associated to Parkinson's disease (p < 10-6) and displaying an epistatic 
(E) effect, or conditional (C) or simultaneous (S) effects with significant deviations of a multiplicative model. The genetic model tested is specified as 
SNP1 genotype * SNP2 genotype.BMC Genomics 2008, 9:360 http://www.biomedcentral.com/1471-2164/9/360
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were sufficiently efficient. Because we are using the same
set of cases and controls in all the validation groups, a
high degree of consistency of results across validations
analyses would be expected a priori. Nonetheless, due to
the small sample size of each group, the many require-
ments for the selection of marker variables, such as the
consistency of strength and direction of result in three rep-
lication groups, and the subjective categorization (single-
locus X2 > 3.84) of results into different types of effects
(epistatic, conditional and simultaneous), a large variabil-
ity in results across validation analyses is reasonable.
The total number of preliminary results varies noticeably
across validation groups (Table 4). This variability illus-
trates the randomness inherent in this type of analysis.
The total number of two-locus combinations selected as
simultaneous or conditional are much more consistent.
Nonetheless, the number of epistatic effects is quite varia-
ble again, perhaps a consequence of the small number of
marker combinations selected under this category.
In addition to the variability in the number of results, it is
important to note the general lack of consistent results
across validation groups. The simultaneous effects were
the most consistent type of result. One two-locus combi-
nation (rs7653784 rs499091) showed up in the original
analysis and the 10 validation samples. Five other combi-
nations with simultaneous effects were consistent in 10
out of the 11 samples, and 28 combinations were consist-
ent in 9 samples. Of the conditional results, thirteen
marker combinations were consistent in 8 samples. Per-
haps because their effect is harder to replicate, only one
epistatic marker combination was present in as much as 5
samples, while 2 combinations were present in 4 samples,
and three combinations in three samples.
Discussion
HFCC is a new computer software for exhaustive genome-
wide analysis of multi-locus association effects in a case-
control design. It carries out different types of statistical
tests to assess a variety of genetic and epistatic models.
HFCC differs from other association or multi-locus meth-
ods in that it can analyze simultaneously multiple sam-
ples or multiple phenotypes, and incorporates several
complementary noise-signal filters, and also post-hoc
analysis tools. To address the enormous computing task,
it is elegantly designed to take advantage of the multiple
CPUs available nowadays in computer servers or clusters.
The goal of HFCC analysis is to find multi-locus marker
combinations which are significantly associated with a
phenotype, especially those displaying interaction effects
which may not be detected in a single-locus analysis. By
setting the type of genetic model, the number of subjects
in each group, the number of replication groups, the sta-
tistical cut-offs for the different tests, and applying differ-
ent noise elimination filters, HFCC can arrive at a
selection of the most promising multi-locus combina-
tions.
Other multi-locus methods to detect gene-gene interac-
tions exist. For example MDR [10] is a method for exhaus-
tive search of high-level multi-locus interactions,
although it is extremely computationally intensive, and
genome-wide searches for epistasis are prohibitive. More
recently a promising Bayesian method (BEAM) has been
suggested as a powerful alternative for detecting epistatic
interactions, although it is not exhaustive and still
requires further improvements to effectively handle the
large SNP datasets commonly used in genome-wide stud-
ies [11]. Other methods, like PLINK [9] or others based on
logistic regression [5], can carry out genome-wide epista-
Table 4: Validation analysis.
Sample Preliminary Results Simultaneous Conditional Epistatic
Original 418,535 19,630 6,706 35
Validation 1 396,708 20,855 6,897 23
Validation 2 283,584 19,270 6,219 18
Validation 3 299,846 19,261 6,000 27
Validation 4 403,475 19,640 6,660 21
Validation 5 337,422 19,575 6,463 22
Validation 6 320,406 18,879 6,230 20
Validation 7 313,653 18,667 5,943 21
Validation 8 294,007 19,255 6,360 26
Validation 9 322,754 18,478 5,772 22
Validation 10 363,194 19,317 5,529 28
Average Count (St. Dev.) 341,235 (47,125) 19,348 (629) 6,253 (419) 24 (5)
Average % 100% 7.92% 2.56% 0.010%
Number of total preliminary results, and number of selected simultaneous, conditional and epistatic two-locus combinations in the original sample, 
and in ten random-placement validation samples. Average numbers (and standard deviations) for the 11 samples, and average percentage of each 
category, are included.BMC Genomics 2008, 9:360 http://www.biomedcentral.com/1471-2164/9/360
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sis tests relatively quick, but are currently limited to two-
or three-locus models, and only perform general tests of
epistasis. HFCC combines a relatively fast computing
algorithm for genome-wide epistasis detection, with the
flexibility to test a variety of different epistatic models in
multi-locus combinations. Our analysis of a simulated
dataset reveals that HFCC has good power, at least as good
as or better than MDR [20], to detect epistatic interactions,
as long as they are relatively strong and common. In the
most extreme simulation, with 5% genotyping error, 5%
missing data, 50% phenocopies, and 50% genetic hetero-
geneity, HFCC still had 71% power to detect some types
of epistasis, although the power for other types of epistasis
was smaller (34–51%). We will need to carry out more
extensive simulations to evaluate the power under differ-
ent conditions and genetic models.
For this illustrative application of the software we have
also analyzed an open-access dataset of Parkinson's dis-
ease patients and unaffected controls. We would like to
emphasize here the importance of these public datasets of
real data to improve the quality of applied research, and
also to foster the development of new methodology.
One of the pecularities of HFCC is the possibility of divid-
ing the case-control sample into replication groups, to
detect only those effects that are consistent across sam-
ples. The number of replication case-control groups to be
used depends on the available dataset (sample size and
number of genetic markers). It is an important analysis
parameter because the overall significance level is a func-
tion of the selected critical value for the test statistic and
the number of replication groups. For the current analysis,
the sample of cases was divided into three replication
groups, and so were the controls. This strategy focuses on
the detection of large and consistent effects, which are
hopefully detectable with the available datasets. It is rea-
sonable to expect that the joint effect of a combination of
genes is larger and more penetrant than each of the single-
locus effects, and therefore under some circumstances
(i.e., not extremely heterogeneous or rare effect), these
multi-locus effects can be identified. The detection of
small, rare or heterogeneous effects may need larger sam-
ples and more complex models.
HFCC allows for a variety of different genetic models and
tests. Different models may be necessary to detect differ-
ent types of effects, such as recessive, dominant or hetero-
zygote effects. The best analysis strategy may depend on
prior knowledge or hypothesis about the trait. An optimal
strategy would apply a selected subset of models which
would maximize the chances of detecting a hypothesized
effect. For example, for this Parkinson's disease study, we
have employed a subset of nine epistatic models which
typically detects recessive effects.
Another characteristic of HFCC analysis is the successive
application of noise-signal filters. Control groups can be
compared against each other to remove background noise
associations. Direction of effect can be taken into account,
so that only those results consistent in strength and direc-
tion across replication samples are selected. A final filter is
able to remove those multi-locus results which are prima-
rily due to quality-control failing markers (ie, in Hardy-
Weinberg disequilibrium, low allele frequency or low call
rate) or to large single-locus effects. The remaining multi-
locus combinations can be categorized into epistatic, con-
ditional and simultaneous effects, and interaction tests
can be used to detect possible epistatic interactions over
and above the marginal effects. The selected markers can
then be included in a validation analysis in an independ-
ent sample. As an illustration, Table 4 displays 30 two-
locus combinations suggestive of displaying epistatic
interactions influencing the development of Parkinson's
disease. It is important to note that due to the small sam-
ple size used in this experiment, these results may not be
reliable, and need re-analysis or confirmation in larger
datasets. The number of combinations selected for a vali-
dation analysis depends on many factors, and tools are
included to help perform this selection.
The Parkinson's disease study reported here can illustrate
several issues regarding the search for epistatic effects in
large datasets. One of the most difficult tasks in large data-
set analysis is selecting the most promising candidate
results. The huge number of statistical tests performed
requires a severe statistical cut-off, or a protocol of data fil-
tering, to be able to select only the most promising results.
For example, the two-locus analysis of a genome-wide
association SNP dataset presented here reveals several hun-
dred thousands two-locus marker combinations at a lib-
eral significance level (i.e., p value < 10-6). Using a stringer
significance level, such as a Bonferroni correction, may be
overly conservative, sometimes potentially missing real
effects. HFCC filters and post-hoc analyses help selecting
the most promising two-locus interactions from a large set
of preliminary findings. For example, all two-marker com-
binations in Table 4 are consistently associated with Park-
ison's disease in three replication groups (overall two-
locus X2 (1 df) in the range 21–30), and they all also devi-
ate from a multiplicative model (case-only X2 (1 df) in the
range 7–33) suggesting an epistatic interaction.
The resampling validation analysis raises an important
issue regarding the difficulty in replicating a result across
different validation samples, a finding that may reflect the
general lack of power to detect these types of effects, espe-
cially in the presence of heterogeneity. With the available
sample size for this study we have approximately 80%
power to detect large common effects (Odds ratio > 3 in a
genotype prevalence > 25%) at a significance level of 0.01BMC Genomics 2008, 9:360 http://www.biomedcentral.com/1471-2164/9/360
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per replication group. However, this small dataset is
underpowered to find more moderate, and perhaps more
realistic, effect sizes. The general lack of consistency sug-
gested by our own sensitivity analysis may be a conse-
quence of the small sample size analyzed. Fung et al.
(2006) claimed that there is no common genetic variant
that exerts a large genetic risk for late-onset Parkinson's
disease in white North Americans. Multi-locus analysis
may, however, reveal the existence of large complex
(multi-locus) genetic effects.
Analysis Guidelines
HFCC provides a tool for the genome-wide study of
epistasis. Its use may depend heavily on the researcher's
goals and the data available. For this reason, it is hard to
provide general guidelines on the optimal parameters for
analysis, but HFCC's flexibility to accommodate to the
specific needs of each study is a great asset.
A key parameter is the number of replication groups.
When the available sample size is fixed, dividing the sam-
ple into more replication groups decreases the power of
the analysis, but also increases the confidence in the
remaining results. For example, the two-locus analysis of
the full Parkinson's dataset in one case-control group with
a Type I error set at 10-6 yields a total of 784,506 prelimi-
nary positive results. The analysis of the same data splitted
in three replication groups, each with alpha = 10-2, yields
only 418,535 results (53% of the single-group results).
There is not an optimal number of replication groups.
Researchers need to select this parameter as well as the sig-
nificance level cut-off to fit their dataset and study design.
For example, a study of three related diseases or pheno-
types suggests the use of three replication groups. In the
case of a single disease, the number of replication groups,
the sample size in each group, and the statistical cut-off
should be chosen depending on the nature of the study. A
strict statistical correction may be necessary if the results
are to be conclusive, while a more relaxed criterion may be
used in a two-stage study where the goal of the prelimi-
nary analysis is to select a subset of markers for subse-
quent validation.
HFCC's flexibility is also possible in the application of
data filters. The results displayed in Table 2 suggest that
the control filter and the direction filter can eliminate
most of the same noise results. The application of either
or both of these filters can therefore depend on the study
design. If a study has many control subjects and a limited
number of cases, it can benefit from using the control fil-
ter. If a study has many affected individuals, then several
replication groups and the direction filter can be used.
There are also 255 possible two-marker genetic models
that can be tested. Many of them are correlated, so it is
probably not necessary to test them all. We suggest using
a small subsample of models that cover the researcher's
hypothesis. For example, for the Parkinson's analysis in
this paper we tested nine simple genetic models. To iden-
tify subsamples of models that may optimize the chances
of discovering epistatic effects of different nature would
need a thorough simulation analysis that is beyond the
scope of the current paper. Another analysis option is to
use more general tests of epistasis, which are also imple-
mented in the software.
Statistical Issues
The two-locus analysis of the full Parkinson's dataset as
presented here comprises a total of 708 × 109 statistical
tests. The two-locus analysis of these data in one case-con-
trol group with a Type I error set at 10-6 yields a total of
784,506 preliminary positive results, about 10% more of
those expected by chance. This false positive inflation is
probably due to the tracking markers (mainly QC-fail
markers) as well as to the correlated nature of some of the
statistical tests, and can be controlled by the use of repli-
cation groups, or by applying more stringent cut-offs if
necessary.
For the simulated dataset, analyzed with only one case-
control group a significance level of 10-2  (chi-square
6.64), the Type I error was actually lower than expected
(approximately around 0.006 on average). These results
demonstrate that HFCC analysis is not only powerful but
can also be conservative, preserving against Types I and II
Errors. More thorough simulations to assess the impact of
sample size, allele frequency, number of replication
groups, and noise filter applications are needed in the
future to understand these issues in detail.
Applying strict multiple testing correction (Bonferroni) to
the Parkison's disease analysis, we do not find any signif-
icant two-locus interactions. The reason for this may be
the small sample size available in the Parkinson's dataset.
But we can still select the most promising two-locus
results for subsequent validation. The key issue is whether
we are concerned with achieving an absolute level of sta-
tistical significance, which may not be properly defined in
this setting given the complexity of the analysis suggested
(multiple testing of correlated hypotheses, independent
replication of results, data filtering steps), or selecting the
most promising markers or marker combinations that
pass a more or less stringent statistical criterion. In either
case, the usefulness of HFCC for selecting marker combi-
nations for later validation is doubtless.
Computational Issues
Multi-locus analysis is computationally intensive and is
therefore limited by computing capabilities. HFCC is a
relatively fast algorithm considering the huge number of
computations it performs. The dataset analyzed in thisBMC Genomics 2008, 9:360 http://www.biomedcentral.com/1471-2164/9/360
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study consists of 396,591 genetic markers, which results
in 78.6 × 109  two-locus marker combinations. Nine
genetic models were tested in the current study, resulting
in a total of 708 × 109 statistical tests. Moreover, these tests
may be carried out in as many as three case-control repli-
cation groups, and also in as many as three control-con-
trol noise-filter groups, so the computing task is
staggering. HFCC is programmed to take advantage of
computer resources by dividing the computing task into
processes which can migrate to the available CPUs in a
computer server or cluster. For the current analysis, we
employed a computer cluster consisting of twelve 3.2 GHz
CPUs, which was able to carry out the full genome-wide
analysis in approximately 5 days.
Another computational complication for multi-locus
analysis is related to RAM memory. The data matrices
need to be loaded onto memory to speed computations,
and therefore a limitation exists for the analysis of very
large datasets (millions of genetic markers or several thou-
sands of subjects) where RAM memory is rapidly
exhausted. This limitation, however, can be solved with
parallel processing techniques (MPI like), such as dividing
the data matrices into smaller subsets which are distrib-
uted around the computer network.
HFCC can perform more complex multi-locus analysis (3-
locus, 4-locus, etc.), but the number of computations
grows exponentially with the number of interacting mark-
ers, and the analysis becomes dependent on computing
resources and time limitations. Depending on these
resources, genome-wide three- or four-locus analysis may
require a two-stage strategy, where some markers are
selected first by single-locus analysis, and then employed
to guide the multi-locus testing [19]. Our exhaustive two-
locus genome-wide analysis of a Parkinson's disease data-
set reveals that pure epistatic effects, as defined here, are
rare (0.01% of the preliminary results). Therefore, a two-
stage strategy for multi-locus analysis may be a more eco-
nomical analysis with minimal information loss. This
statement assumes that we had power to detect these epi-
static effects, that more complex interactions behave as
two-locus ones, and that Parkinson's disease is represent-
ative of other diseases. Our results suggest the use of a con-
ditional two-stage strategy, where a liberal single-locus
threshold is first used to select loci with marginal effects,
and then these markers are used against the full panel for
multi-locus analysis. This conclusion is similar to some
previous suggestions [5,19] but not all [21], confirming
that a liberal single-locus cut-off (i.e., p < .05) greatly
reduces the computational task while minimizing the
probability of discarding potential epistatic loci.
It is also important to note that linkage disequilibrium
(LD) is unaccounted for in our analyses. LD reflects an
association among markers and therefore can affect the
results of some tests. For example, it can produce a signif-
icant case-only chi-squared test. Nonetheless, HFCC's
algorithm and analysis filters seem to prevent this bias. In
the case where one marker is associated with several mark-
ers in LD, these results are detected in the last stage of
marker selection.
Conclusion
In summary, we propose that genome-wide multi-locus
analysis is performed on available datasets of common
diseases, because they can exploit the large genetic data-
sets and computing resources becoming available, to
open a new phase of genetic analysis. The analysis of Par-
kinson's disease reported here represents the first exhaus-
tive genome-wide epistasis search on a real dataset,
effectively handling hundred of thousands of genetic
markers, and demonstrating its feasibility. Due to the
small sample size, however, these results are only illustra-
tive and require re-analysis or confirmation in larger data-
sets. These multi-locus analyses would not substitute
conventional single-locus analysis but add a new layer of
genome-wide association studies, allowing the identifica-
tion of new candidate markers for further validation.
HFCC is a new genome-wide multi-locus software, which
allows the user a high degree of control over analysis
parameters, so that data analysis can be tailored to the
specific needs of each project. HFCC can have a great
impact on the discovery of the genetic causes of common
diseases, especially to identify those multi-locus effects
that may not be detectable using the available single-locus
methods. The discovery of new genes affecting a disease
may be useful as predictive tools or to find new therapeu-
tic targets. HFCC has multiple applications, not only in
the study of disease phenotypes, but also of other qualita-
tive traits, and can be used in clinical trials or pharmaco-
genetics studies.
Availability and requirements
HFCC is written in C and freely available for linux plat-
forms from this Website: http://www.neocodex.com/en/
hfcc.0.5.zip
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